EXTENDED INDUCTION RESPONSE IN PATIENTS TREATED WITH MIRIKIZUMAB WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN THE LUCENT TRIALS

Geert R. D'Haens  1     Peter D.R. Higgins  2     Laurent Peyrin-Biroulet  3     Bruce E. Sands  4     Scott D. Lee  5     Richard Moses  6     Isabel Redondo  7     Rodrigo Escobar  8     Nathan Morris  8     Taku Kobayashi  9    
1 Amsterdam University Medical Centers, Amsterdam, Netherlands
2 University of Michigan, Ann Arbor, United States
3 University Hospital of Nancy, Vandoeuvre-les-Nancy, France
4 Icahn School of Medicine at Mount Sinai, New York, United States
5 University of Washington Medical Center, Seattle, United States
6 Eli Lilly and Company, Indianapolis, United States
7 Eli Lilly Portugal, Lisbon, Portugal
8 Lilly S.A., Alcobendas, Spain
9 Kitasato University Kitasato Institute Hospital, Minato-ku, Japan

Topic
Endoscopy, Histopathology, IBD

Conference
UEG Week 2023

Citation
United European Gastroenterology Journal 2023; 11 (Supplement 8)


Login to access library content

Login

Do you need help setting up your myUEG account?
Contact us at [email protected]

New to myUEG?

Create myUEG account

Social Sharing